Physician

M Ashraf Meelu, MD

According to 2025 Medicare claims, M. Meelu, MD (NPI: 1255489027) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from Charles, MD. This provider's primary affiliated billing organization is CANCER AND BLOOD DISORDERS TREATMENT CENTER LLC (NPI: 1104353374; TIN: 300665061) and primary practice location at 20602-3228.

Meelu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 766 traditional Medicare patients, billed 371,336 HCPCS/CPT codes, and received $1,303,264 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,315 prescription claims across 270 beneficiaries totaling $6,821,816 in drug costs, led by Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj). DME data shows 47 claims. Open Payments data shows 73 records totaling $2,335. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,801,706 to $6,821,816. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,480 to $1,226.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	583	245,723	$1,238,156
2016	577	225,877	$1,150,463
2017	552	305,397	$1,448,275
2018	605	253,728	$1,363,242
2019	623	241,559	$1,217,790
2020	587	310,846	$1,164,253
2021	668	416,171	$1,459,077
2022	701	336,055	$1,425,128
2023	831	333,375	$1,744,728
2024	766	371,336	$1,303,264

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	131	1,083	$1,801,706
2016	145	1,413	$2,694,257
2017	153	1,462	$2,770,305
2018	158	1,626	$3,551,599
2019	153	1,381	$3,923,179
2020	159	1,522	$4,138,775
2021	170	1,583	$5,224,006
2022	193	1,511	$4,159,644
2023	222	1,556	$3,786,156
2024	270	2,315	$6,821,816

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	124	$8,893
2016	N/R	96	$7,809
2017	N/R	70	$3,141
2018	N/R	23	$1,016
2019	N/R	24	$954
2020	N/R	11	$1,767
2021	N/R	26	$1,024
2022	N/R	N/R	N/R
2023	N/R	34	$1,813
2024	N/R	47	$1,700

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	625	1,761	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	316	1,869	$69
96372	Injection of drug or substance under skin or into muscle	362	1,940	$11
36415	Insertion of needle into vein for collection of blood sample	701	2,895	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	697	2,969	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	31	870	$612,496
Revlimid	Lenalidomide	32	896	$543,668
Pomalyst	Pomalidomide	19	532	$439,212
Keytruda	Pembrolizumab	28	588	$312,387
Opdivo	Nivolumab	23	574	$299,311

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$821
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$496
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	12	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	73	$2,335	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for M. Ashraf Meelu, MD?

Tedicare shows public-source Medicare data for M. Ashraf Meelu, MD (NPI 1255489027), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does M. Ashraf Meelu, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to M. Ashraf Meelu, MD?

M. Ashraf Meelu, MD is linked to CANCER AND BLOOD DISORDERS TREATMENT CENTER LLC (billing NPI 1104353374) in the available physician profile data.

Does M. Ashraf Meelu, MD have Open Payments data?

M. Ashraf Meelu, MD has 73 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.